{
    "clinical_study": {
        "@rank": "179",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 09, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04273763"
        },
        "id_info": {
            "org_study_id": "2019NCP1.0",
            "nct_id": "NCT04273763"
        },
        "brief_title": "Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)",
        "official_title": "Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Second Affiliated Hospital of Wenzhou Medical University",
                "agency_class": "Other"
            },
            "collaborator": {
                "agency": "WanBangDe Pharmaceutical Group Co.,Ltd.",
                "agency_class": "Other"
            }
        },
        "source": "Second Affiliated Hospital of Wenzhou Medical University",
        "oversight_info": {
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "Compare the efficacy and safety of Bromhexine Hydrochloride Tablets combined with standard\n      treatment/ standard treatment in patients with suspected and mild, or common novel\n      coronavirus pneumonia (COVID-19).\n\n      Random, open, group sequential design."
        },
        "overall_status": "Enrolling by invitation",
        "start_date": {
            "@type": "Actual",
            "#text": "February 16, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "April 30, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "April 15, 2020"
        },
        "phase": "N/A",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Sequential Assignment",
            "primary_purpose": "Treatment",
            "masking": "None (Open Label)"
        },
        "primary_outcome": [
            {
                "measure": "Time to clinical recovery after treatment",
                "time_frame": "within 14 days from the start of medication",
                "description": "Defined as random to fever, respiratory rate return to normal and cough remission over 48 hours."
            },
            {
                "measure": "Rate of aggravation",
                "time_frame": "within 14 days from the start of medication",
                "description": "Aggravation was defined as(one of them): respiratory distress, RR \u2265 30 times / min; SpO2 \u2264 93% in resting state; arterial partial pressure of oxygen (PaO2) /concentration of oxygen (FiO2) \u2264 300mmHg"
            }
        ],
        "secondary_outcome": [
            {
                "measure": "Clinical remission rate",
                "time_frame": "within 14 days from the start of medication",
                "description": "Clinical remission was defined as (one of them): sustained (more than 48 hours) alleviation of illness based on symptom (fever, cough, dyspnea, myalgia, diarrhea and so on) all being absent and no evidence for progression."
            },
            {
                "measure": "Dynamic changes of oxygenation index",
                "time_frame": "within 14 days from the start of medication",
                "description": "oxygenation index"
            },
            {
                "measure": "Time to cure",
                "time_frame": "within 14 days from the start of medication",
                "description": "time of Clinical recovery, negative COVID-19 nucleic acid results and CT recovery"
            },
            {
                "measure": "rate to cure",
                "time_frame": "within 14 days from the start of medication",
                "description": "proportion of Clinical recovery, negative COVID-19 nucleic acid results and CT recovery among infected patients"
            },
            {
                "measure": "Time to defervescence",
                "time_frame": "within 14 days from the start of medication",
                "description": "defervescence is defined as below 37 Celcius degrees\uff08ear temperature\uff09"
            },
            {
                "measure": "Time to cough remission",
                "time_frame": "within 14 days from the start of medication"
            },
            {
                "measure": "Time to dyspnea remission",
                "time_frame": "within 14 days from the start of medication"
            },
            {
                "measure": "Days of supplemental oxygenation",
                "time_frame": "within 14 days from the start of medication"
            },
            {
                "measure": "Rate of patients with requring supplemental oxygen",
                "time_frame": "within 14 days from the start of medication"
            },
            {
                "measure": "Rate of patients with mechanical ventilation",
                "time_frame": "within 14 days from the start of medication"
            },
            {
                "measure": "Time of negative COVID-19 nucleic acid results",
                "time_frame": "within 14 days from the start of medication"
            },
            {
                "measure": "Rate of negative COVID-19 nucleic acid results",
                "time_frame": "within 14 days from the start of medication"
            },
            {
                "measure": "Rate of ICU admission",
                "time_frame": "within 14 days from the start of medication"
            },
            {
                "measure": "28-day mortality",
                "time_frame": "From the first day of screening to the day of follow-up (28 days)"
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "60"
        },
        "condition": [
            "Novel Coronavirus Pneumonia",
            "2019-nCoV"
        ],
        "arm_group": [
            {
                "arm_group_label": "Group A",
                "arm_group_type": "Experimental",
                "description": "Treatment group"
            },
            {
                "arm_group_label": "Group B",
                "arm_group_type": "Active Comparator",
                "description": "Control group"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "Bromhexine Hydrochloride Tablets",
                "description": "Bromhexine Hydrochloride Tablets",
                "arm_group_label": "Group A"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Arbidol Hydrochloride Granules",
                "description": "Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.",
                "arm_group_label": [
                    "Group A",
                    "Group B"
                ]
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Recombinant Human Interferon \u03b12b Spray",
                "description": "Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.",
                "arm_group_label": [
                    "Group A",
                    "Group B"
                ]
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged between 18 and 80 years (Including 18and 80years, male or female).\n\n          -  One of them:\n\n               1. Laboratory (RT-PCR) and clinical symptoms confirmed case of novel coronavirus\n                  pneumonia (COVID-19).\n\n               2. Patients diagnosed clinically as suspected cases.\n\n          -  Ability to communicate well with researchers and sign the informed consent Form (ICF)\n             voluntarily.\n\n        Exclusion Criteria:\n\n          -  ALT\u22655 times of ULN, level of total bilirubin\u22653 times of ULN, or Cr\u22651.5 times of ULN.\n\n          -  Patients with serious severe liver disease.\n\n          -  Excluded who diagnosed as pneumonia patients with novel coronavirus infection of\n             severe type and critical type. \u3010Diagnostic criteria reference the official guideline\n             \"Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial\n             Version 5) \"\u3011.\n\n          -  Patients with previous history of severe gastrointestinal diseases such as gastric\n             ulcers and bleeding.\n\n          -  Patients with lactose intolerance.\n\n          -  Patients who are allergic to the components of this medicine (Major components:\n             Bromhexine Hydrochloride; excipient: starch, lactose, magnesium stearate).\n\n          -  Positive serum pregnancy test result for women with childbearing potential at\n             screening or lactating women.\n\n          -  Other circumstances that the researcher considers inappropriate to participate in this\n             study."
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "80 Years",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "XIAN SHEN, phd",
            "role": "Study Chair",
            "affiliation": "The 2nd Affiliated Hospital of Wenzhou Medical University"
        },
        "location": {
            "facility": {
                "name": "The Second AffIliated Hospital of Wenzhou Medical University",
                "address": {
                    "city": "Wenzhou",
                    "state": "Zhejiang",
                    "zip": "325000",
                    "country": "China"
                }
            }
        },
        "location_countries": {
            "country": "China"
        },
        "verification_date": "March 2020",
        "study_first_submitted": "February 14, 2020",
        "study_first_submitted_qc": "February 14, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "February 18, 2020"
        },
        "last_update_submitted": "March 19, 2020",
        "last_update_submitted_qc": "March 19, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "March 23, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "condition_browse": {
            "mesh_term": [
                "Coronavirus Infections",
                "Pneumonia"
            ]
        },
        "intervention_browse": {
            "mesh_term": [
                "Interferons",
                "Bromhexine"
            ]
        },
        "patient_data": {
            "sharing_ipd": "No"
        }
    }
}